Financials
This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQANIK
| Beta | 1.11 |
|---|---|
| Shares Outstanding | 14.5M |
| Average Volume (10 days) | 135.3K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Hold |
|---|
| Strong Buy | 0 | |
|---|---|---|
| Buy | 0 | |
| Hold | 3 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
David Colleran EVP, General Counsel, Corp Sec | 1,500 Buy May 11, 2022 |
|---|---|
David Colleran EVP, General Counsel, Corp Sec | 1,500 Buy Mar 14, 2022 |
Jeffery Scott Thompson Director | 2,000 Buy Mar 11, 2022 |
Michael L. Levitz EVP, CFO, Treasurer | 4,000 Buy Mar 11, 2022 |
Cheryl R. Blanchard Director, President, CEO, Director | 4,287 Buy Mar 11, 2022 |